0A6I.LSE Soligenix, Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0A6I.LSE undervalued?
Graham numberThe Graham number of Soligenix, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Soligenix, Inc. fundamental analysis
No fundamental analysis for Soligenix, Inc. yet.
Soligenix, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulato…
Full company profileFinancial statements of Soligenix, Inc. are not available yet.
Soligenix, Inc. dividends
Soligenix, Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 0.0625:1 on Jun 6, 2024.
Who owns Soligenix, Inc.
- Insiders 4.59%
- Institutions 6.72%
- Public & others 88.69%
- Free float 21.7M
Soligenix, Inc. company profile
- Company name
- Soligenix, Inc.
- Ticker
- 0A6I.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- 29 Emmons Drive, Princeton, NJ, United States, 08540
- Phone
- 609 538 8200
- Website
- soligenix.com
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Soligenix, Inc. management
4- Dr. Christopher J. Schaber Ph.D.Chairman of the Board of Directors, CEO & President · born 1966
- Mr. Jonathan L. Guarino CPA, CGMASenior VP, CFO & Corporate Secretary · born 1973
- Dr. Oreola Donini Ph.D.Senior VP & Chief Scientific Officer · born 1972
- Mr. Adam T. RumageSenior VP of Project Management & Regulatory Affairs